Ellipses Pharma
Professor Tobias Arkenau is a seasoned expert in oncology drug development, currently serving as Chief Medical Officer and Global Head of Drug Development at Ellipses Pharma since May 2022. Prior to this role, Arkenau held prominent positions including Clinical Lead Oncology Service Line at HCA International Ltd and Executive Medical Director at Sarah Cannon Research Institute UK, where the focus was on drug development for gastrointestinal cancers and melanoma. With a strong academic background as a Professor at UCL and experience as a Team Leader in Clinical Drug Development at the University of New South Wales, Arkenau's clinical research expertise was further enhanced as a Senior Clinical Research Fellow at the Royal Marsden Hospital. Early career experience includes roles in internal medicine and oncology at Hospital Bremen East. Arkenau holds MD and PhD degrees in medicine from Medical School Hanover and Martin Luther University Halle.
This person is not in any teams
This person is not in any offices
Ellipses Pharma
Ellipses Pharma is an international drug development company, focused exclusively on the advancement of innovative cancer treatments through the clinic. New treatments for cancer are not progressing fast enough. Ellipses is dedicated to making a difference. Headquartered in London, Ellipses is run by a world class leadership team, overseeing a rapidly growing pipeline of high quality clinical oncology opportunities. Supported by privileged partnerships with leading academic institutions, research bodies, universities, Big Pharma and extensive professional networks, Ellipses Pharma aims to be the most direct route from the research laboratory to patients for cancer treatments. Clinical trials are the route to developing more cancer treatments. All too often they have become overly complex and expensive, slowing down the progress of new discoveries and new treatments for patients. We streamline the clinical trials process that so often inhibits the progress of new potential drugs with one overarching objective - making more treatments available to patients. Ellipses provides a permanent source of capital for the development of cancer assets via a scalable business model, and is able to conduct multiple oncology clinical trials in parallel. Supported by our Scientific Affairs Group which comprises many of the world's leading oncologists, Ellipses is taking a new, ambitious approach to significantly impact the cancer drug development market.